CA2401357A1 - Agent inhibiteur de decomposition de tissu - Google Patents

Agent inhibiteur de decomposition de tissu Download PDF

Info

Publication number
CA2401357A1
CA2401357A1 CA002401357A CA2401357A CA2401357A1 CA 2401357 A1 CA2401357 A1 CA 2401357A1 CA 002401357 A CA002401357 A CA 002401357A CA 2401357 A CA2401357 A CA 2401357A CA 2401357 A1 CA2401357 A1 CA 2401357A1
Authority
CA
Canada
Prior art keywords
antibody
dna
ser
gly
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002401357A
Other languages
English (en)
Inventor
Hidemi Saito
Toshiaki Tsunenari
Etsuro Onuma
Koh Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2401357A1 publication Critical patent/CA2401357A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un inhibiteur de décomposition de tissu contenant une substance qui inhibe la liaison entre un peptide associé à une hormone parathyroïdienne et son récepteur.
CA002401357A 2000-02-28 2000-08-30 Agent inhibiteur de decomposition de tissu Abandoned CA2401357A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000052414 2000-02-28
JP2000-52414 2000-02-28
PCT/JP2000/005886 WO2001064249A1 (fr) 2000-02-28 2000-08-30 Inhibiteur de decomposition de tissu

Publications (1)

Publication Number Publication Date
CA2401357A1 true CA2401357A1 (fr) 2001-09-07

Family

ID=18573930

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002401357A Abandoned CA2401357A1 (fr) 2000-02-28 2000-08-30 Agent inhibiteur de decomposition de tissu

Country Status (2)

Country Link
CA (1) CA2401357A1 (fr)
WO (1) WO2001064249A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
TW202340257A (zh) 2018-02-09 2023-10-16 日商小野藥品工業股份有限公司 雙特異性抗體

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04228089A (ja) * 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd 高カルシウム血症治療・予防剤
EP0539491A1 (fr) * 1990-07-13 1993-05-05 The Regents Of The University Of California Analogues de parathormone modifies aux positions 3, 6 ou 9
US5849695A (en) * 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
JPH07316195A (ja) * 1994-05-25 1995-12-05 Nippon Kayaku Co Ltd 新規なＰＴＨｒＰ関連ペプチド及びその用途
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
ATE363289T1 (de) * 1995-02-20 2007-06-15 Yukio Kato Heilmittel für arthrosis deformans und entzündliche gelenkerkrankungen
CA2219361C (fr) * 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
US5660826A (en) * 1995-06-06 1997-08-26 The Regents Of The University Of California Therapeutic sepsis treatment using antagonists to PTHrP
BR9713294A (pt) * 1996-09-26 2000-10-17 Chugai Pharmaceutical Co Ltd "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano"
JP4372240B2 (ja) * 1997-05-15 2009-11-25 中外製薬株式会社 悪液質治療剤
JP2000080100A (ja) * 1998-06-17 2000-03-21 Japan Tobacco Inc 副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体
CZ20004753A3 (cs) * 1998-06-26 2002-06-12 Chugai Seiyaku Kabushiki Kaisha Terapeutické činidlo na hyperkalcinemickou krizi

Also Published As

Publication number Publication date
WO2001064249A1 (fr) 2001-09-07

Similar Documents

Publication Publication Date Title
AU750021B2 (en) Cachexia remedy
AU744146B2 (en) Antibody against human parathormone related peptides
AU753131B2 (en) Remedies for hypercalcemic crisis
EP2502996A2 (fr) Anticorps anti-FGF23 et composition pharmaceutique le comprenant
JPH1180025A (ja) 悪液質治療剤
CA2401357A1 (fr) Agent inhibiteur de decomposition de tissu
TWI274586B (en) Ameliorating agent for symptoms resulting from joint diseases
EP1197225A1 (fr) REMEDES CONTRE LES MALADIES CAUSEES PAR PTH OU PTHrP
US7655227B1 (en) Agents for ameliorating low vasopressin level
AU2003203622B2 (en) Cachexia remedy
US20030049211A1 (en) Remedies and preventives for dental diseases
EP1195164A1 (fr) Remedes contre l'hypercalcemie chimio-resistante
AU2004222761A1 (en) Remedies for drug-resistant hypercalcemia
AU2005203262A1 (en) Remedies for diseases caused by PTH or PTHrP
CZ398499A3 (cs) Léčivo proti kachexii
MXPA99010364A (en) Cachexia remedy
AU3824702A (en) Antibody against human parathormone related peptides
WO2002092133A1 (fr) Inhibiteurs d'angiogenese

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead